'I just thought that it was such an impossible thing': A qualitative study of barriers and facilitators to discontinuing long-term use of benzodiazepine receptor agonists using the Theoretical Domains Framework.

Tom Lynch, Cristín Ryan, Cathal A Cadogan
Author Information
  1. Tom Lynch: School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dubin, Ireland.
  2. Cristín Ryan: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
  3. Cathal A Cadogan: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland. ORCID

Abstract

INTRODUCTION: Existing interventions to reduce long-term benzodiazepine receptor agonist (BZRA) use lack theoretical underpinning and detailed descriptions. This creates difficulties in understanding how interventions work and how to replicate them in practice. The Theoretical Domains Framework (TDF) can be used to identify behaviour change determinants to target during intervention development.
OBJECTIVE: To explore barriers and facilitators to discontinuing BZRA use from the perspective of both current and previous long-term BZRA users.
DESIGN/SETTING AND PARTICIPANTS: Semistructured TDF-based interviews were conducted with community-based individuals with current or previous experience of long-term BZRA use. Data were recorded, transcribed and analysed using the framework method.
RESULTS: Twenty-eight individuals were interviewed. Despite commonalities in perceived barriers/facilitators to discontinuing BZRA use within individual TDF domains, individual PARTICIPANTS had different experiences of identified determinants of BZRA discontinuation. For example, both similarities and differences existed within and between each participant group in terms of knowledge of the appropriate duration of BZRA use ('Knowledge' domain) and experience of withdrawal symptoms ('Reinforcement' domain). Compared to previous users, current users typically anticipated more barriers to discontinuing BZRA use and fewer positive consequences of discontinuation.
CONCLUSION: This study reports on barriers and facilitators to discontinuing BZRA use from the perspectives of current and previous long-term users. The findings highlight the challenging nature of BZRA discontinuation and a multitude of barriers that impact PARTICIPANTS' behaviour regarding BZRA use. Future work will involve developing a theory-based intervention to support BZRA discontinuation in primary care.
PATIENT CONTRIBUTION: The study included patients as PARTICIPANTS.

Keywords

References

  1. Addiction. 2009 Jan;104(1):13-24 [PMID: 18983627]
  2. Drugs Aging. 2018 Jun;35(6):493-521 [PMID: 29705831]
  3. Drugs R D. 2017 Dec;17(4):493-507 [PMID: 28865038]
  4. Aust Prescr. 2015 Oct;38(5):152-5 [PMID: 26648651]
  5. Eur J Clin Pharmacol. 2021 Feb;77(2):171-177 [PMID: 33006626]
  6. Curr Opin Psychiatry. 2005 May;18(3):249-55 [PMID: 16639148]
  7. Ir J Psychol Med. 2019 Sep;36(3):163-167 [PMID: 31524127]
  8. Br J Gen Pract. 2008 Jun;58(551):417-22 [PMID: 18505619]
  9. Can Fam Physician. 2018 May;64(5):339-351 [PMID: 29760253]
  10. Addiction. 2020 Sep;115(9):1618-1639 [PMID: 31985127]
  11. Implement Sci. 2012 Apr 24;7:37 [PMID: 22530986]
  12. Soc Sci Med. 2006 Mar;62(5):1237-49 [PMID: 16143440]
  13. J Med Toxicol. 2013 Jun;9(2):155-62 [PMID: 23404347]
  14. Eur J Clin Pharmacol. 2021 Jun;77(6):903-912 [PMID: 33410969]
  15. J Gerontol Soc Work. 2014;57(8):872-88 [PMID: 24918963]
  16. BMC Med Res Methodol. 2013 Sep 18;13:117 [PMID: 24047204]
  17. Qual Health Res. 2005 Nov;15(9):1277-88 [PMID: 16204405]
  18. Implement Sci. 2015 Nov 16;10:161 [PMID: 26573745]
  19. J Psychopharmacol. 2013 Nov;27(11):967-71 [PMID: 24067791]
  20. Int J Nurs Stud. 2013 May;50(5):587-92 [PMID: 23159157]
  21. J Gen Intern Med. 2007 Mar;22(3):303-7 [PMID: 17356959]
  22. Pilot Feasibility Stud. 2019 Mar 12;5:41 [PMID: 30923626]
  23. Int J Ment Health Nurs. 2021 Oct;30 Suppl 1:1395-1406 [PMID: 34101332]
  24. Patient. 2017 Feb;10(1):1-15 [PMID: 27282559]
  25. Cochrane Database Syst Rev. 2015;(5):CD009652 [PMID: 26106751]
  26. BMC Fam Pract. 2013 Dec 13;14:191 [PMID: 24330388]
  27. Addiction. 2010 Nov;105(11):1870-4 [PMID: 20456294]
  28. Health Expect. 2018 Feb;21(1):138-148 [PMID: 28766816]
  29. Implement Sci. 2017 Jun 21;12(1):77 [PMID: 28637486]
  30. N Engl J Med. 2017 Mar 23;376(12):1147-1157 [PMID: 28328330]
  31. Addiction. 2010 Nov;105(11):1876-7 [PMID: 21064247]
  32. Implement Sci. 2012 Apr 24;7:38 [PMID: 22531013]
  33. Int J Qual Health Care. 2007 Dec;19(6):349-57 [PMID: 17872937]
  34. BMC Pharmacol Toxicol. 2015 Jul 04;16:19 [PMID: 26141716]
  35. Br J Clin Pharmacol. 2018 Jun;84(6):1354-1363 [PMID: 29488252]
  36. Ther Adv Psychopharmacol. 2021 Jan 17;11:2045125320981174 [PMID: 33520155]
  37. J Med Internet Res. 2016 Nov 7;18(11):e286 [PMID: 27821383]
  38. Qual Saf Health Care. 2005 Feb;14(1):26-33 [PMID: 15692000]
  39. Ther Adv Psychopharmacol. 2021 Mar 16;11:2045125321991274 [PMID: 33796265]
  40. Health Expect. 2022 Feb;25(1):355-365 [PMID: 34862703]
  41. Br J Psychiatry. 2006 Sep;189:213-20 [PMID: 16946355]
  42. Eur Psychiatry. 2015 Nov;30(8):1037-47 [PMID: 26545257]
  43. Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481 [PMID: 29543325]

MeSH Term

GABA-A Receptor Agonists
Humans
Medication Adherence
Qualitative Research
Receptors, GABA-A

Chemicals

GABA-A Receptor Agonists
Receptors, GABA-A

Word Cloud

Created with Highcharts 10.0.0BZRAuselong-termbarriersdiscontinuingdiscontinuationcurrentprevioususersTheoreticalDomainsFrameworkbehaviourfacilitatorsstudyinterventionsbenzodiazepinereceptorworkTDFdeterminantsinterventionindividualsexperienceusingwithinindividualparticipantsdomainqualitativeINTRODUCTION:ExistingreduceagonistlacktheoreticalunderpinningdetaileddescriptionscreatesdifficultiesunderstandingreplicatepracticecanusedidentifychangetargetdevelopmentOBJECTIVE:exploreperspectiveDESIGN/SETTINGANDPARTICIPANTS:SemistructuredTDF-basedinterviewsconductedcommunity-basedDatarecordedtranscribedanalysedframeworkmethodRESULTS:Twenty-eightinterviewedDespitecommonalitiesperceivedbarriers/facilitatorsdomainsdifferentexperiencesidentifiedexamplesimilaritiesdifferencesexistedparticipantgrouptermsknowledgethe appropriateduration'Knowledge'withdrawalsymptoms'Reinforcement'ComparedtypicallyanticipatedfewerpositiveconsequencesCONCLUSION:reportsperspectivesfindingshighlightchallengingnaturemultitudeimpactparticipants'regardingFuturewillinvolvedevelopingtheory-basedsupportprimarycarePATIENTCONTRIBUTION:includedpatients'Ijustthoughtimpossiblething':agonistsZ-drugsbenzodiazepines

Similar Articles

Cited By (8)